Hassan Ashktorab to Histone Deacetylase Inhibitors
This is a "connection" page, showing publications Hassan Ashktorab has written about Histone Deacetylase Inhibitors.
Connection Strength
0.478
-
Singh A, Natu A, Anthony F, Muthu H, Khade B, Smoot DT, Ashktorab H, Gupta S. The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells. Clin Epigenetics. 2025 Oct 08; 17(1):168.
Score: 0.226
-
Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol. 2020 Feb 14; 26(6):598-613.
Score: 0.153
-
Fatemi M, Paul TA, Brodeur GM, Shokrani B, Brim H, Ashktorab H. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer. 2014 Jan 15; 120(2):172-80.
Score: 0.099